‘The Top Line’: What makes the Fierce 15 honorees tick, Fierce Biotech Summit’s spotlight on gene editing and the bear market

‘The Top Line’: What makes the Fierce 15 honorees tick, Fierce Biotech Summit’s spotlight on gene editing and the bear market
30 September 2022

Amphista interview starts at 10:41

Fierce Pharma – View full story

Amphista Therapeutics opens Granta Park research facility

Amphista Therapeutics opens Granta Park research facility
30 September 2022
Cambridge Independent – View full story

Amphista enters two collaborations for protein degrading therapeutics

Amphista enters two collaborations for protein degrading therapeutics
6 May 2022
European Pharmaceutical Manufacturer – View full story

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Amphista Lands Megadeals to Smash Cancer using Protein Degradation
6 May 2022
Heal Security – View full story

Amphista and BMS partner to develop protein degradation therapies

Amphista and BMS partner to develop protein degradation therapies
6 May 2022
Pharma Advancement – View full story

Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera

Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
5 May 2022
Scrip – View full story

BMS, Merck Partner with Amphista Therapeutics to Develop Targeted Protein Degraders

BMS, Merck Partner with Amphista Therapeutics to Develop Targeted Protein Degraders
5 May 2022
Precision Oncology News – View full story

Amphista and BMS partner to develop protein degradation therapies

Amphista and BMS partner to develop protein degradation therapies
5 May 2022
Pharmaceutical Technology – View full story

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Amphista Lands Megadeals to Smash Cancer using Protein Degradation
5 May 2022
Labiotech.eu – View full story

Two Pharma Giants Link Up With Amphista on Protein Degradation Projects

Two Pharma Giants Link Up With Amphista on Protein Degradation Projects
5 May 2022
FDANews – View full story
Article requires subscription to view full text